CEDARS-SINAI MEDICAL CENTER

Researchers discovered that CDK4/6 inhibitors create an immunosuppressive tumor microenvironment in some HR+/HER2- breast cancers, leading to treatment resistance through gamma delta T-cells and specific macrophage populations.

Percheron Therapeutics has licensed HMBD-002, a first-in-class monoclonal antibody targeting the VISTA immune checkpoint, from Hummingbird Bioscience in a deal worth up to $290 million.

Recent research shows increasing overtreatment of prostate cancer in older men with limited life expectancy, with radiation therapy use rising from 16% to 39% despite guidelines recommending against such interventions.

Gilead Sciences and Merck's phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrated statistically significant improvement in progression-free survival with Trodelvy plus Keytruda compared to Keytruda with chemotherapy in metastatic TNBC patients.

A clinical trial found that hospital-based addiction consultation services more than doubled the rate of medication initiation for opioid use disorder during hospitalization (57.3% vs 26.7% with usual care).

ABVC BioPharma has secured three global licensing agreements valued at $959 million across psychiatric disorders, ophthalmology, and oncology, expecting to generate approximately $19 million in cash revenue in 2025.

The FDA has approved Itovebi in combination with Ibrance and Faslodex for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, based on the INAVO120 trial results.

Recent data from six randomized controlled trials involving 1,887 patients demonstrates significant benefits of endovascular therapy (EVT) in large-core stroke patients, with functional independence rates of 19.5% versus 7.9% for medical management alone.

Recent FDA approvals of transcatheter tricuspid valve devices, including Evoque and TriClip, are transforming treatment options for tricuspid regurgitation patients who historically avoided surgery.

• Antibody-drug conjugates (ADCs) represent a promising class of targeted therapies in breast cancer, delivering chemotherapy directly to cancer cells. • Clinical trials are exploring over 150 ADCs, including LCB84, showing potential in patients with heavily pre-treated or resistant cancers. • ADCs like Enhertu and Trodelvy have demonstrated significant efficacy, even in tumors with low target expression, shifting paradigms in treatment. • Researchers emphasize the importance of understanding the distinct side effect profiles of different ADCs for optimal patient management.